Project Grant R01HL174644
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$773K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $252,285 to St. Jude Children's Research Hospital Inc. to support a 5-year training program focused on basic and translational research in pediatric classical hematology. The program will support three postdoctoral fellows conducting hypothesis-driven research to elucidate the mechanisms of non-malignant blood diseases and uncover new therapeutic targets. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $560,828 to Yale University to conduct research on the role of linker histones in regulating the lymphoid differentiation potential of hematopoietic stem and progenitor cells. The research aims to define the molecular pathway by which specific linker histone isoforms or abundance influence the lineage output of multipotent...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $146,876 to the Coriell Institute for Medical Research to develop new methods for expanding functional hematopoietic stem cells (HSCs) from cryopreserved umbilical cord blood (UCB) samples. The project aims to optimize an approach using PPAR-α agonists, which have been shown to significantly expand long-term functional UCB HSCs...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $295,438 to the University of Florida to develop a novel ex vivo expansion platform for human hematopoietic stem cells (HSCs). The goal is to significantly increase the availability of suitable HSC donors for hematopoietic stem cell transplantation and improve post-transplant recovery, which is critical for treating life-threatening blood and bone marrow...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $296,892 to support research aimed at understanding the molecular regulation of lymphoid lineage priming in both steady state and regenerative hematopoiesis. The research, conducted by The Children's Hospital Corporation (Boston Children's Hospital), will use single-cell sequencing and lineage tracing approaches to elucidate how the transcription factor TCF15...
This Project Grant award of $734,607 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the key endothelial mechanisms that direct hematopoietic stem cells (HSCs) across the blood vessel wall and into their niche. The research, conducted by Boston Medical Center Corporation, will use high-resolution live cell imaging, structure-function studies, and in vivo proximity-dependent biotinylation in zebrafish to define the endothelial...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $160,518 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Research Institute. The 5-year grant, which began on August 15, 2024, supports the development of the principal investigator into an independent researcher in the field of immune modulation cell therapy for critically ill children, particularly those who have undergone...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the Trustees of Indiana University, Indianapolis provides $792,498 to investigate the regulation of hematopoietic stem cells (HSCs) under low oxygen tension (hypoxia). The research aims to understand the signaling and metabolic alterations in HSCs under hypoxic conditions and explore the potential to manipulate these processes in normoxic conditions to improve HSC...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $680,321 to the Fred Hutchinson Cancer Center in Seattle, WA to conduct research on how the protein DLK1 regulates hematopoietic stem cell (HSC) quiescence through phase separation-mediated inhibition of receptor signaling. The key objectives are to determine if DLK1 maintains and/or expands quiescent HSCs, elucidate how DLK1 interactions...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $435,804 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to elucidate the mechanistic basis for the selective advantage of the acquired DDX41R525H mutation in hematopoietic stem cells (HSCs) of patients with germline DDX41 mutations, who develop myelodysplastic syndrome (MDS) and related myeloid malignancies. The...